loading
Galmed Pharmaceuticals Ltd stock is traded at $1.99, with a volume of 401.34K. It is up +0.51% in the last 24 hours and up +9.94% over the past month. Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
See More
Previous Close:
$1.98
Open:
$1.95
24h Volume:
401.34K
Relative Volume:
0.24
Market Cap:
$4.49M
Revenue:
-
Net Income/Loss:
$-6.91M
P/E Ratio:
-0.6104
EPS:
-3.26
Net Cash Flow:
$-6.14M
1W Performance:
+8.74%
1M Performance:
+9.94%
6M Performance:
-32.10%
1Y Performance:
-46.16%
1-Day Range:
Value
$1.79
$2.09
1-Week Range:
Value
$1.61
$2.09
52-Week Range:
Value
$1.15
$23.80

Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile

Name
Name
Galmed Pharmaceuticals Ltd
Name
Phone
-
Name
Address
-
Name
Employee
6
Name
Twitter
@GalmedPharma
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
GLMD's Discussions on Twitter

Compare GLMD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GLMD
Galmed Pharmaceuticals Ltd
1.99 4.47M 0 -6.91M -6.14M -3.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades

Date Action Analyst Rating Change
May-22-20 Downgrade B. Riley FBR Buy → Neutral
Feb-04-20 Initiated Craig Hallum Buy
Jan-30-20 Resumed Cantor Fitzgerald Overweight
Dec-02-19 Initiated Canaccord Genuity Buy
Dec-12-18 Initiated B. Riley FBR Buy
Aug-02-18 Reiterated Maxim Group Buy
Jul-13-18 Initiated Stifel Buy
Jul-12-18 Initiated Cantor Fitzgerald Overweight
Jun-12-18 Reiterated H.C. Wainwright Buy
Mar-15-18 Upgrade Maxim Group Hold → Buy
Feb-14-18 Downgrade Maxim Group Buy → Hold
Feb-12-18 Reiterated H.C. Wainwright Buy
Nov-15-17 Initiated ROTH Capital Buy
Aug-08-17 Reiterated H.C. Wainwright Buy
Jul-31-17 Reiterated Maxim Group Buy
Aug-01-16 Reiterated Maxim Group Buy
Jul-06-16 Resumed ROTH Capital Buy
Mar-28-16 Resumed H.C. Wainwright Buy
Jun-23-15 Initiated H.C. Wainwright Buy
May-06-15 Initiated Sun Trust Rbsn Humphrey Buy
View All

Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News

pulisher
Jul 25, 2025

What drives Galmed Pharmaceuticals Ltd. stock priceExceptional profit potential - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Galmed Pharmaceuticals to Hold Special Meeting on Share Capital Increase - TipRanks

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Galmed Pharmaceuticals Ltd. stockFree Stock Market Beginners Guide - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Galmed Pharmaceuticals Ltd. Stock Analysis and ForecastMarket-crushing stock picks - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Galmed Pharmaceuticals Ltd. a good long term investmentTurbocharged investment results - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

The Role of News and Events in Galmed Pharmaceuticals Ltd Inc. (GLMD) Price Performance - investchronicle.com

Jul 21, 2025
pulisher
Jul 20, 2025

Why India’s Pharmaceutical Stocks Are on the Rise High Accuracy Trade SignalsRapid market gains - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 19, 2025

Solara Active Pharma Sciences Limited (SOLARAPP)’s Trend in 2025Free Stock Market Forecast Reports - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

PLAB Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Galmed Pharmaceuticals Ltd. stock price move sharplyFree Insider Trading Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Galmed Pharmaceuticals Ltd. stock attracts strong analyst attentionSafe and Scalable Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Galmed Pharmaceuticals Ltd. stock performs during market volatilitySteady Profit Stock Forecasts - Newser

Jul 15, 2025
pulisher
Jun 03, 2025

Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire

Jun 03, 2025
pulisher
May 27, 2025

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Galmed Pharmaceuticals Unveils Biomarker Signature for Aramchol, Expanding Market Potential - TipRanks

May 27, 2025
pulisher
May 27, 2025

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - Longview News-Journal

May 27, 2025
pulisher
May 24, 2025

Wall Street Zen Upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) to Sell - Defense World

May 24, 2025
pulisher
May 23, 2025

Galmed Pharmaceuticals: Q1 Earnings Snapshot - New Haven Register

May 23, 2025
pulisher
May 22, 2025

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Galmed Pharmaceuticals Reports Q1 2025 Financial Results and Advances in Oncology - TipRanks

May 22, 2025
pulisher
May 22, 2025

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

May 22, 2025
pulisher
May 15, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World

May 15, 2025
pulisher
May 14, 2025

Galmed Pharmaceuticals Unveils Promising Aramchol Results in PSC Models - TipRanks

May 14, 2025
pulisher
May 14, 2025

Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramc - GuruFocus

May 14, 2025

Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):